C. M. Balch, Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, issue.36, p.6199206, 2009.
DOI : 10.1200/JCO.2009.23.4799

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793035/pdf

A. Hauschild, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, vol.380, issue.9839, p.35865, 2012.
DOI : 10.1016/S0140-6736(12)60868-X

P. B. Chapman, Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, p.250716, 2011.
DOI : 10.1056/NEJMoa1103782

C. Robert, Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib, New England Journal of Medicine, vol.372, issue.1, p.3039, 2015.
DOI : 10.1056/NEJMoa1412690

J. Larkin, -Mutated Melanoma, New England Journal of Medicine, vol.371, issue.20, p.186776, 2014.
DOI : 10.1056/NEJMoa1408868

F. S. Hodi, Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, p.71123, 2010.
DOI : 10.1056/NEJMoa1003466

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549297/pdf

C. Robert, Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, New England Journal of Medicine, vol.364, issue.26, p.251726, 2011.
DOI : 10.1056/NEJMoa1104621

C. Robert, Mutation, New England Journal of Medicine, vol.372, issue.4, p.32030, 2015.
DOI : 10.1056/NEJMoa1412082

URL : https://hal.archives-ouvertes.fr/hal-00872683

J. S. Weber, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.16, issue.4, p.37584, 2015.
DOI : 10.1016/S1470-2045(15)70076-8

A. Ribas, « Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, vol.16, p.90818, 2015.
DOI : 10.1016/s1470-2045(15)00083-2

C. Robert, Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, p.252132, 2015.
DOI : 10.1056/NEJMoa1503093

D. Schadendorf, Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, Journal of Clinical Oncology, vol.33, issue.17, pp.1889-94, 2015.
DOI : 10.1200/JCO.2014.56.2736

C. Allayous, Donn??es actualis??es d???efficacit?? et de tol??rance de l???ipilimumab en ????vie r??elle???? via la cohorte Melbase, Annales de Dermatologie et de V??n??r??ologie, vol.143, issue.12, 1989.
DOI : 10.1016/j.annder.2016.09.243

F. Deilhes, D. Lea, V. Sibaud, F. Puisset, S. Boulinguez et al., Donn??es d???efficacit?? en vie r??elle des inhibiteurs de PD1??dans le m??lanome m??tastatique, Données d'efficacité en vie réelle des inhibiteurs de PD1 dans le mélanome métastatique, p.178, 2016.
DOI : 10.1016/j.annder.2016.09.208

E. Colle, Efficacit?? et tol??rance ????en vie r??elle???? des immunoth??rapies anti-PD1??chez les patients atteints de m??lanome stade III inop??rable ou IV au sein de la cohorte nationale MelBase, Annales de Dermatologie et de V??n??r??ologie, vol.142, issue.12, 2015.
DOI : 10.1016/j.annder.2015.10.088

E. A. Eisenhauer, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, p.22847, 2009.
DOI : 10.1016/j.ejca.2008.10.026

A. P. Algazi, Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies, Cancer, vol.33, issue.15 suppl, p.33443353, 2016.
DOI : 10.1016/j.jaut.2015.08.020

A. Deschamps, C. Mignard, A. Samain, A. D. Modeste, and E. P. Joly, ??valuation de la r??ponse des m??lanomes muqueux et choro??diens ?? l???immunoth??rapie par anti-CTLA4??et/ou anti-PD1, Évaluation de la réponse des mélanomes muqueux et choroïdiens à l'immunothérapie par anti-CTLA4 et/ou anti-PD1 », p.196, 2016.
DOI : 10.1016/j.annder.2016.09.239

J. Larkin, Wild-Type Advanced Melanoma, JAMA Oncology, vol.1, issue.4, p.43340, 2015.
DOI : 10.1001/jamaoncol.2015.1184

K. M. Fife, Determinants of Outcome in Melanoma Patients With Cerebral Metastases, Journal of Clinical Oncology, vol.22, issue.7, p.12931300, 2004.
DOI : 10.1200/JCO.2004.08.140

Y. Nakamura, Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy, Oncotarget, vol.7, p.7740415, 2016.
DOI : 10.18632/oncotarget.12677

URL : http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=12677&path%5B%5D=40163

P. F. Ferrucci, « Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann. Oncol, vol.27, p.73238, 2016.
DOI : 10.1093/annonc/mdx059

J. Felix, Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy, International Immunopharmacology, vol.40, p.46673, 2016.
DOI : 10.1016/j.intimp.2016.09.030

J. S. Weber, Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma, Journal of Clinical Oncology, vol.35, issue.7, p.78592, 2017.
DOI : 10.1200/JCO.2015.66.1389

H. Teulings, Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis, Journal of Clinical Oncology, vol.33, issue.7, p.77381, 2015.
DOI : 10.1200/JCO.2014.57.4756

M. A. Postow, Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma, New England Journal of Medicine, vol.366, issue.10, p.92531, 2012.
DOI : 10.1056/NEJMoa1112824

S. Demaria, Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated, International Journal of Radiation Oncology*Biology*Physics, vol.58, issue.3, p.86270, 2004.
DOI : 10.1016/j.ijrobp.2003.09.012

S. J. Dovedi, Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade, Cancer Research, vol.74, issue.19, p.545868, 2014.
DOI : 10.1158/0008-5472.CAN-14-1258

URL : http://cancerres.aacrjournals.org/content/canres/74/19/5458.full.pdf

J. Doyen, Clinical Outcomes of Metastatic Melanoma Treated With Checkpoint Inhibitors and Multisite Radiotherapy, JAMA Dermatology, vol.153, issue.10, 2017.
DOI : 10.1001/jamadermatol.2017.2222

A. Modesto, Immunoth??rapie anti-PD-1??et radioth??rapie concomitante dans le m??lanome m??tastatique??: donn??es cliniques pr??liminaires d???efficacit?? et de tol??rance, Annales de Dermatologie et de V??n??r??ologie, vol.143, issue.12, p.199, 2016.
DOI : 10.1016/j.annder.2016.09.244

L. Zimmer, Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma, European Journal of Cancer, vol.75, p.4755, 2017.
DOI : 10.1016/j.ejca.2017.01.009

L. Spain, T. Schmid, M. Gore, and E. J. Larkin, Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features, European Journal of Cancer, vol.75, p.24344, 2017.
DOI : 10.1016/j.ejca.2016.12.040

S. Champiat, Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Annals of Oncology, vol.27, issue.4, p.55974, 2016.
DOI : 10.1093/annonc/mdv623

A. M. Menzies, Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab, Annals of Oncology, vol.28, p.36876, 2017.
DOI : 10.1093/annonc/mdw443